SMARCB1 and epithelioid sarcoma: Tazemetostat, an EZH2 inhibitor, was tested in patients with locally advanced or metastatic epithelioid sarcoma with documented loss of INI1 expression with IHC or biallelic SMARCB1 alterations in a Phase 2 trial.